asiapacific-oncologists-2017-scientifictracks

17 / 17

Page 34
Notes:
conferenceseries.com
Volume 9, Issue 11 (Suppl) J Cancer Sci Ther
ISSN: 1948-5956 JCST, an open access journal Asia Pacific Oncologists 2017
November 20-22, 2017
November 20-22, 2017 Melbourne, Australia
14th Asia Pacific
Oncologists Annual Meeting
Soluble CD160 enhances antitumor immunity against murine H22 hepatocarcinoma in vivo
Han Xiao
Wuhan Medical and Health Center for Women and Children, China
The glycosylphosphatidylinositol (GPI)-anchored CD160 is a relatively new co-inhibitory molecular and expressed mainly
on cytolytic cells such as CD8+ T cells, natural killer (NK) T cells, NK cells and some CD4+ T cells. CD160 on virus-specific
CD8+ T cells is up-expressed and generally associated with T cells dysfunction, thus considered as an exhaustion marker.
However, CD160 expression on tumor-specific CD8+ T cells and its contribution to tumor-specific CD8+ T cells impairment
remains unclear. Here, we try to decipher its regulatory effects on tumor-specific CD8+ T cells function and seek a new target
for tumor therapy. CD8+ T cells were separated from splenocytes of tumor-bearing mice and expression of CD160 and HVEM
was detected. A eukaryotic expression plasmid (psCD160) was constructed, expressing the extracellular domain of murine
CD160 (soluble CD160) which could block the interaction between CD160 and HVEM by binding HVEM. The activity of
proliferation and cytolysis and secretion of cytokines by CD8+ T cells were measured after being incubated by soluble CD160
and specific tumor antigen. The treatment effects of psCD160 combined with tumor-vaccine in vivo were observed by H22
hepatocarcinoma mice tumor model. The up-regulated expression of CD160 on CD8+ T cells from tumor-bearing mice was
confirmed to be related to cells dysfunction, characterized by lower proliferation and cytotoxicity activity and less cytokine
production. Soluble CD160 enhances CD8+ T cells, resulting in increased IFN-γ, IL-2 and TNF-α secretion and cytolysis
against target tumor cells in vitro. The administration of soluble CD160 accompanied with tumor-vaccine inhibited tumor
growth and prolonged the survival of tumor-bearing mice. Expression of CD160 defined a relatively decreased activity subset
of CD8+ T cells and soluble CD160 augments immunological activity and function of tumor-specific CD8+ T cells and acquired
significant treatment effects against existent tumor cells in vivo.
Biography
Han Xiao has graduated from the Clinical Medicine Department of Tongji Medical College of Huazhong University of Science and Technology. She has received a
Doctor’s degree in Molecular Biology. Her research interests are in tumor research, treat primary tumor and metastasis by the combination delivery of chemotherapy
drugs, tumor vaccine and gene therapy to activate or block some signal transduction.
Han Xiao, J Cancer Sci Ther 2017, 9:11 (Suppl)
DOI: 10.4172/1948-5956-C1-117